Tag: mismatch repair deficient (dMMR) cancer

Home / mismatch repair deficient (dMMR) cancer

Categories

Dostarlimab-gxly with chemotherapy is approved by the FDA for endometrial cancer

August 2023: Dostarlimab-gxly (Jemperli, GlaxoSmithKline), followed by dostarlimab-gxly as a single agent, was approved by the Food and Drug Administration for the treatment of primary advanced or re...
mismatch-repair-deficient-dmmr-cancer

Scan the code